Search results
Results from the WOW.Com Content Network
Based on these factors, Intellia Therapeutics won't get a boost to its stock price anywhere close to what Wall Street predicts in the next 12 months. That alone doesn't mean the stock isn't a buy ...
In this article you are going to find out whether hedge funds think Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a good investment right now. We like to check what the smart money thinks first ...
Intellia prioritized NTLA-2002 and nex-z while discontinuing the NTLA-3001 program and other early-stage initiatives. The reorganization will result in a 27% workforce reduction and a projected $8 ...
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. [3] NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. [4]
The localized segments provide current weather observations, and high and low temperatures observed since 12:00 a.m. local time for a given city; MinuteCast forecasts, incremental forecasts (pioneered by AccuWeather, Inc. [3]) for the next hour; at-a-glance forecasts for the current day and the day after; extended forecasts (which, in addition ...
They also began increasing the range of their forecast from 15 days to 25 days, 45 days, and (by 2016) to 90 days. These hyper-extended forecasts have been compared to actual results several times and shown to be misleading, inaccurate, and sometimes less accurate than simple predictions based on National Weather Service averages over a 30-year ...
Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.
AccuWeather 3 hours ago Pineapple Express to soak western US with rain, snow. Days of rain are forecast to hit portions of the Northwest and California, bringing the risk of flooding and landslides.